Previous close | 26.44 |
Open | 26.61 |
Bid | 26.23 x 0 |
Ask | 26.25 x 0 |
Day's range | 26.25 - 26.82 |
52-week range | 23.53 - 37.50 |
Volume | |
Avg. volume | 74,758 |
Market cap | 149.501B |
Beta (5Y monthly) | 0.58 |
PE ratio (TTM) | N/A |
EPS (TTM) | -0.04 |
Earnings date | 30 July 2024 - 05 Aug 2024 |
Forward dividend & yield | 1.56 (5.89%) |
Ex-dividend date | 09 May 2024 |
1y target est | N/A |
Pfizer (PFE) has been one of the stocks most watched by Zacks.com users lately. So, it is worth exploring what lies ahead for the stock.
– After six months of additional follow-up, clinical benefit rate (63%), overall response rate (41.9%), median progression-free survival (11.2 months), and safety profile of vepdegestrant in combination with palbociclib were consistent with data previously reported at SABCS in December 2023 – – At the recommended Phase 3 dose of 200 mg vepdegestrant in combination with palbociclib, patients achieved a median progression-free survival of 13.9 months (95% CI: 8.1-NR) – – Across all vepdegestrant d
Pfizer will pay up to $250 million to settle more than 10,000 U.S. lawsuits over cancer risks associated with its discontinued heartburn drug Zantac, the Financial Times reported on Thursday. The settlement was disclosed in a court filing in Delaware last week, and is aimed at reducing Pfizer's potential liability, the report added. Pfizer did not immediately reply to Reuters' request for comment.